vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results

vTv Therapeutics (NASDAQ:VTVT) announced its quarterly earnings results on Wednesday. The biotechnology company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44, Zacks reports. The company had revenue of $36.84 million during the quarter, compared to analyst estimates of $20.00 million.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT traded down $0.44 during midday trading on Wednesday, hitting $31.67. 43,048 shares of the company’s stock traded hands, compared to its average volume of 51,935. The firm’s fifty day moving average price is $35.96 and its two-hundred day moving average price is $33.87. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VTVT. Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Evercore began coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target on the stock. Roth Mkm initiated coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. Finally, BTIG Research restated a “buy” rating and set a $49.00 target price on shares of vTv Therapeutics in a report on Wednesday, March 11th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics during the 4th quarter worth $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter worth $731,000. Finally, Geode Capital Management LLC increased its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.